The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.
复制标题
DOI：
10.1155/2012/743193
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
O'Regan R
中科院分区：
文献类型：
--
作者：
Mitri Z;Constantine T;O'Regan R
人表皮生长因子受体2（HER 2）在约20-30%的乳腺癌肿瘤中过表达。它与更侵袭性的疾病、更高的复发率和更高的死亡率相关。曲妥珠单抗是一种HER 2受体阻滞剂，已成为治疗HER 2阳性乳腺癌的标准治疗。曲妥珠单抗的有效性已在研究和临床实践中得到充分验证。在临床试验中，将曲妥珠单抗添加到标准治疗化疗中已被证明可改善早期和转移性HER 2阳性乳腺癌的结局。曲妥珠单抗最具临床意义的副作用是心肌细胞损伤的风险，导致充血性心力衰竭的发展。对曲妥珠单抗耐药模式的出现导致了新的单克隆抗体和其他靶向药物的发现，这些药物旨在克服曲妥珠单抗耐药并改善诊断为HER 2阳性乳腺癌患者的生存率。
Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in research as well as in clinical practice. The addition of Trastuzumab to standard of care chemotherapy in clinical trials has been shown to improve outcomes for early stage as well as metastatic HER2 positive breast cancer. The most clinically significant side effect of Trastuzumab is the risk of cardiac myocyte injury, leading to the development of congestive heart failure. The emergence of patterns of resistance to Trastuzumab has led to the discovery of new monoclonal antibodies and other targeted agents aimed at overcoming Trastuzumab resistance and improving survival in patients diagnosed with HER2 positive breast cancers.